Core Viewpoint - Cidara Therapeutics is actively participating in the Guggenheim Securities SMID Cap Biotech Conference, showcasing its innovative drug-Fc conjugate (DFC) immunotherapies aimed at improving patient care for serious diseases [1][2]. Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop novel DFCs, which consist of targeted small molecules or peptides linked to a human antibody fragment [3]. - The lead DFC candidate, CD388, is designed for long-acting antiviral treatment to provide universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3]. - CD388 received Fast Track Designation from the U.S. FDA in June 2023, and the company completed Phase 2b enrollment in December 2024 [3]. - Cidara has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]. Event Participation - Jeffrey Stein, Ph.D., President and CEO of Cidara, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 1:30 PM ET [1]. - Cidara will engage in one-on-one investor meetings during the conference, with interested investors encouraged to contact their Guggenheim representative [2].
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference